Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers
Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers
复制标题
检测21基因复发评分在预测两个医疗中心乳腺癌患者预后和治疗反应中的临床应用
DOI：
10.1080/07357907.2017.1405015
复制
发表时间：
2017-01-01
影响因子：
2.4
通讯作者：
Sun, Xin
中科院分区：
文献类型：
--
作者：
Xiao, Guodong;Meng, Jinying;Sun, Xin
摘要探讨西北地区中国地区浸润性乳腺癌的最佳治疗策略。复发评分(RS)越低，复发率越低。具有中高21基因RS的患者接受辅助治疗的复发风险较低。有RS结果的年轻患者(⩾31)倾向于更频繁地接受辅助治疗，然而，那些RS结果中等的患者倾向于等待而不接受化疗。这些结果表明，基于RS的精准医学将允许个性化的诊断和治疗，从而获得更好的结果和节省医疗资源。
ABSTRACT To determine the most suitable strategy in treating patients with invasive breast cancer from Northwest China. Lower recurrence score (RS) correlated with lower recurrence ratio. Patients having a medium-high 21-gene RS who received adjuvant therapy presented lower recurrence risk. Younger patients having RS results (⩾31) tended to accept adjuvant therapy more often, however, those having intermediate RS results were inclined to wait and did not receive chemotherapy. These results suggested that RS-based precision medicine will allow individualized diagnosis and treatment, resulting in better outcomes and preserved medical resources.